Compare Abeona Therapeutics Inc (ABEO) vs Dow Inc (DOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Dow Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Dow Inc trades at $29.12 (market cap $20.64B). The key difference: Dow Inc is far larger — about 55.3× Abeona Therapeutics Inc's market cap, and Dow Inc pays a 4.89% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | DOW | |
|---|---|---|
Market Cap | $373.32M | $20.64B |
Sector | Health | Basic Materials |
52-Week High | $7.23 | $41.87 |
52-Week Low | $4.17 | $20.65 |
Enterprise Value | $228.22M | $36.42B |
Dividend Yield | — | 4.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
DOW trades at $28.64, up 3.36% today, with a bearish technical signal despite recent earnings beats. The stock shows negative profitability with a net income margin of -7.24% and ROE of -17.85%, though valuation ratios like P/S of 0.5 appear modest. Cash flow trends indicate operational challenges, with 2025 operating cash flow at $1.03B down from prior years, while the company maintains a dividend payout.
Outlook remains cautious due to weak fundamentals and bearish technicals, but analyst consensus price target of $36.11 suggests 26% upside. Key risks include sustained negative margins and high debt levels, while potential catalysts hinge on cost-cutting effectiveness and market demand recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →
